Rhabdomyosarcoma Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
Dallas, TX (PRWEB) January 03, 2015 -- The report "Rhabdomyosarcoma Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma is a cancerous tumor of the muscles that are attached to the bones. It mostly occurs in areas naturally lacking in skeletal muscle such as the head and neck, the urogenital tract, and the arms or legs. The cause of rhabdomyosarcoma is unknown. It is a rare tumor with only several hundred new cases per year in the United States. The most common symptom is a mass that may or may not be painful and other symptoms vary depending on location of the tumor. Complete Report is Available @ http://www.reportsnreports.com/reports/321892-rhabdomyosarcoma-pipeline-review-h2-2014.html .
It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects. Companies discussed in this Rhabdomyosarcoma Pipeline Review H2 2014 report include Arisaph Pharmaceuticals, Inc., Bellicum Pharmaceuticals, Inc., Celgene Corporation, Eisai Co., Ltd., GlaxoSmithKline plc, Neotropix, Inc., Novartis AG.
Drugs profile discussed in this Rhabdomyosarcoma Pipeline Review H2 2014 report include ARI-4175, Cell Therapy for GD2 Expressing Solid Tumors, celyvir, Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3, NY-ESO-1 for Oncology, E-7438, everolimus, NTX-010, paclitaxel albumin bound, pazopanib hydrochloride. Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=321892 .
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rhabdomyosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Rhabdomyosarcoma - Overview 7
Pipeline Products for Rhabdomyosarcoma - Comparative Analysis 8
Rhabdomyosarcoma - Therapeutics under Development by Companies 9
Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Rhabdomyosarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Rhabdomyosarcoma - Products under Development by Companies 13
Rhabdomyosarcoma - Products under Investigation by Universities/Institutes 14
Rhabdomyosarcoma - Companies Involved in Therapeutics Development 15
Rhabdomyosarcoma - Therapeutics Assessment 22
Drug Profiles 32
ARI-4175 - Drug Profile 32
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 34
celyvir - Drug Profile 35
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3, and NY-ESO-1 for Oncology - Drug Profile 37
E-7438 - Drug Profile 38
everolimus - Drug Profile 40
NTX-010 - Drug Profile 45
paclitaxel albumin bound - Drug Profile 47
pazopanib hydrochloride - Drug Profile 51
Rhabdomyosarcoma - Recent Pipeline Updates 56
Rhabdomyosarcoma - Dormant Projects 69
Rhabdomyosarcoma - Discontinued Products 70
Appendix 71
List of Tables
Number of Products under Development for Rhabdomyosarcoma, H2 2014 7
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Rhabdomyosarcoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2014 15
Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2014 16
Rhabdomyosarcoma - Pipeline by Celgene Corporation, H2 2014 17
Rhabdomyosarcoma - Pipeline by Eisai Co., Ltd., H2 2014 18
Rhabdomyosarcoma - Pipeline by GlaxoSmithKline plc, H2 2014 19
Rhabdomyosarcoma - Pipeline by Neotropix, Inc., H2 2014 20
Rhabdomyosarcoma - Pipeline by Novartis AG, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Rhabdomyosarcoma Therapeutics - Recent Pipeline Updates, H2 2014 56
Rhabdomyosarcoma - Dormant Projects, H2 2014 69
Rhabdomyosarcoma - Discontinued Products, H2 2014 70
List of Figures
Number of Products under Development for Rhabdomyosarcoma, H2 2014 7
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Top 10 Targets, H2 2014 23
Number of Products by Stage and Top 10 Targets, H2 2014 24
Number of Products by Top 10 Mechanism of Actions, H2 2014 26
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 27
Number of Products by Top 10 Routes of Administration, H2 2014 28
Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, ReportsnReports, http://www.reportsnreports.com, +1 (888) 391-5441, [email protected]
Share this article